[Palliative and supportive therapy in cases of renal cell carcinoma].
At the time of diagnosis, 25-30% of all patients with renal cell carcinoma already present with metastatic disease. Furthermore, 20-30% of patients with renal cell carcinoma will have progressive disease despite radical nephrectomy with complete tumor resection. In this review, we discuss the current therapeutic options for patients with metastatic renal cell carcinoma: These include palliative radical nephrectomy, surgery of metastasis, tumor embolisation and medical treatment options (e.g. immunotherapy, chemotherapy and targeted therapy), as well as supportive pain treatment.
Kurosch
M
M
Urologische Universitätsklinik, Ruprecht-Karls-Universität, 69120, Im Neuenheimer Feld 110, Heidelberg, Deutschland. Martin.Kurosch@med.uni-heidelberg.de
Buse
S
S
Bedke
J
J
Wagener
N
N
Haferkamp
A
A
Hohenfellner
M
M
D002292:Carcinoma, Renal Cell / Q000150:complications / Q000556:secondary* / Q000628:therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000150:complications / Q000628:therapy*; D008297:Male; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D010166:Palliative Care / Q000379:methods*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D013727:Terminal Care / Q000379:methods